Biography for Ryan McBride
Ryan McBride is an award-winning journalist who writes about the life sciences industry. Prior to joining FierceMarkets, he was a freelance journalist and served as a correspondent at Xconomy for more than two years. His stories have appeared in The Boston Globe, the Boston Business Journal, The Motley Fool, and many other publications. In recent years, he has also given guest lectures to graduate students at Boston University’s Center for Science & Medical Journalism. Earlier in his career, he held staff reporter positions at Mass High Tech, Providence Business News, and The Westerly Sun. Ryan enjoys spending time with his family and exploring mountains and beaches in New England. Follow Ryan on Twitter at @RyanMFierce or send him e-mail here.
Articles by Ryan McBride
Big Pharma and academic groups have made more progress in joining forces on advancing software for translational research on a pre-competitive basis.
Qlucore, a provider of scientific software, has won €600,000 ($801,360) over three years from the European Commission's 7th Framework Program to develop algorithms for use in personalizing treatment of hepatitis C virus.
Clinicians have found help from a new mobile app to gauge risks of coronary events in patients with heart disease, guiding them in designing treatment plans.
The Center for Brains, Minds and Machines, based in Cambridge, MA, is one of three new centers to win funding from the NSF's Science and Technology Centers Integrative Partnerships.
Veeva Systems has filed paperwork as expected to raise up to $150 million in an initial public offering. The fast-growing provider of cloud-based software for sales groups in life sciences would like to list its shares on the New York Stock Exchange under the symbol "VEEV."
Treato CEO Ido Hadari has been trying to convince pharma companies that his startup's software offers advances from so-called "social media listening" applications.
Lab7 Systems, an Austin-based provider of biotech software, has released a set of free software tools for studying data from next-generation DNA sequencing systems. The open source toolkit is called BioBuilds.
In an InformationWeek profile, GlaxoSmithKline touts the benefits of a new online collaboration system, including the savings on travel expenses and satisfaction of the pharma giant's customers.
Enzymatics is expanding its offerings in the DNA sequencing market with the buyout of startup ArcherDx, which provides kits and software for evaluating cancer treatment. Add up the cash, Enzymatics equity and potential milestone fees in the deal, and the buyout could be worth up to $50 million.
Video games have been gaining momentum in healthcare because of various patient benefits, and Genentech's foundation has awarded grant money to propel more games about fighting cancer into the hands of pediatric patients, Medical Marketing & Media reported.